Richard Dolinar
Research Subjects
Richard Dolinar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Frank Lavernia
C North Broward Diabetes Center , Pompano Beach , FL
2 shared publicationsArizona Endocrinology Center Clinical Endocrinologist
1 shared publicationChristine G. Kohn
B University of Connecticut School of Medicine, Farmington, CT & UConn/Hartford Hospital Evidence-based Practice Center , Hartford , CT , USA
1 shared publicationElaine Nguyen
D Idaho State University College of Pharmacy , Meridian , ID , USA
1 shared publicationS. Luke Leininger
1 shared publicationSteven Edelman
1 shared publication
Latest Publications
- 29 May 2019
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 131 (5) , 335-341
The non-medical switching of prescription medications
Non-medical switching of medication, whereby a patient’s treatment regimen is changed for reasons other than efficacy, side effects, or adherence, is often related to drug formulary changes aimed at reducing drug costs. In the era of healthcare reform, while cost-cutting measures are important, there is considerable evidence that non-medical switching, particularly when applied to medication used to treat chronic conditions such as diabetes, may impact patient outcomes, medication-taking behavior, and use of health care services. Ultimately, overall costs may be increased, as savings by insurers are mitigated by higher costs to the healthcare system as a whole, such as extra administration, treatment failure from new medicines, and increased adverse events. The emergence of biosimilar and follow-on biologic treatments raises further questions among patients receiving biologic treatments, with patient advocacy groups calling for clear legislation to ensure that patients with complex or chronic conditions continue to receive effective, evidence-based medications for their disease. This article will discuss non-medical switching in the US, taking into account the different parties involved such as patients, health care providers and pharmacists, payers, and pharmacy benefit managers, with the aim of providing a detailed overview of this complex and evolving topic.
- 29 May 2019
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 131 (5) , 335-341
The non-medical switching of prescription medications
Non-medical switching of medication, whereby a patient’s treatment regimen is changed for reasons other than efficacy, side effects, or adherence, is often related to drug formulary changes aimed at reducing drug costs. In the era of healthcare reform, while cost-cutting measures are important, there is considerable evidence that non-medical switching, particularly when applied to medication used to treat chronic conditions such as diabetes, may impact patient outcomes, medication-taking behavior, and use of health care services. Ultimately, overall costs may be increased, as savings by insurers are mitigated by higher costs to the healthcare system as a whole, such as extra administration, treatment failure from new medicines, and increased adverse events. The emergence of biosimilar and follow-on biologic treatments raises further questions among patients receiving biologic treatments, with patient advocacy groups calling for clear legislation to ensure that patients with complex or chronic conditions continue to receive effective, evidence-based medications for their disease. This article will discuss non-medical switching in the US, taking into account the different parties involved such as patients, health care providers and pharmacists, payers, and pharmacy benefit managers, with the aim of providing a detailed overview of this complex and evolving topic.
- 1 February 2018
- Published by Elsevier in Endocrine Practice
- Vol. 24 (2) , 195-204
A Guide to Follow-on Biologics and Biosimilars with a Focus on Insulin
- 1 February 2018
- Published by Elsevier in Endocrine Practice
- Vol. 24 (2) , 195-204
A Guide to Follow-on Biologics and Biosimilars with a Focus on Insulin
- 1 January 2009
- Published by Touch Medical Media, Ltd. in US Endocrinology
- Vol. 05 (01)
The Importance of Good Insulin Injection Practices in Diabetes Management
Time constraints are often significant when treating patients with diabetes with insulin. In such settings, focus is often placed on the type of insulin the patient is taking, with an even greater emphasis placed on the amount. However, how much emphasis is placed on the practical aspects of insulin use? Is the patient using proper injection techniques? Are the insulin syringes or pens being cared for correctly? Are needles being quietly re-used without the medical staff’s knowledge? Are sharps being disposed of safely? Diabetes education regarding the proper use of insulin takes much time and effort. Without it, however, the appropriate type of insulin at the correct dose might not necessarily give the intended outcome. Instead, marked glycemic excursions could occur, leaving the goal of good diabetes control unachievable and the medical staff baffled.
- 1 January 2009
- Published by Touch Medical Media, Ltd. in US Endocrinology
- Vol. 05 (01)
The Importance of Good Insulin Injection Practices in Diabetes Management
Time constraints are often significant when treating patients with diabetes with insulin. In such settings, focus is often placed on the type of insulin the patient is taking, with an even greater emphasis placed on the amount. However, how much emphasis is placed on the practical aspects of insulin use? Is the patient using proper injection techniques? Are the insulin syringes or pens being cared for correctly? Are needles being quietly re-used without the medical staff’s knowledge? Are sharps being disposed of safely? Diabetes education regarding the proper use of insulin takes much time and effort. Without it, however, the appropriate type of insulin at the correct dose might not necessarily give the intended outcome. Instead, marked glycemic excursions could occur, leaving the goal of good diabetes control unachievable and the medical staff baffled.
- 30 June 2006
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 7 (5) , 328-333
Pay for Performance Means Compliance-Based Care
- 30 June 2006
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 7 (5) , 328-333
Pay for Performance Means Compliance-Based Care